RAPT rapt.com Total Asset Value of Company

RAPT (RAPT Therapeutics, Inc.) - company brandmark

This price chart for the total assets of RAPT Therapeutics, Inc. (RAPT), valued at 137.11, demonstrates the company's financial foundation. Risks are concentrated on the trial results of oncology and inflammation drugs. The business relies on a staff of immunologists attracted by stock options and research freedom. The high barrier to entry in the sector is driven by strict FDA oversight and the patent protection of unique chemical formulas.

RAPT (RAPT Therapeutics, Inc.) Company Total Assets history from 07/04/2022 to 03/14/2026

Analytical breakdowns and data insights for company RAPT Therapeutics, Inc. (RAPT)

- share price and expert price forecast:
Price RAPT Therapeutics Inc.|RAPT - Price Target Chart
- market capitalization data:
Market Valuation RAPT Therapeutics, Inc.|RAPT - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share RAPT Therapeutics|RAPT - Book Capitalization|Market Capitalization to Book Value Ratio rapt.com|RAPT - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio RAPT Therapeutics, Inc.|RAPT - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio rapt.com|RAPT - Company Aggregate Debts|Debts to Book Capitalization RAPT Therapeutics, Inc.|RAPT - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings RAPT Therapeutics|Interim Coverage Ratio rapt.com
- net income and valuation multiples indicators:
RAPT - Company Net Income
Fundamental valuation:RAPT Therapeutics, Inc.
Manufactured products of RAPT Therapeutics

Total assets determine the aggregate resource potential of the business, calculated inversely via return on assets (ROA) to assess the scale of controlled capital. The dynamics of this metric allow for the mitigation of risks associated with freezing funds in illiquid instruments during periods of stagnant demand. An analysis of total assets (via ROA) on the GURU.Markets platform visualizes the financial stability of RAPT Therapeutics, Inc. (RAPT). The growth of resources here reflects the capitalization of strategic partnerships in immunological pharma, enhancing the company's investment attractiveness for M&A.

Key competitors

ARGX: Aggregate Business Assets|Aggregate Company Assets BioNTech|Abivax - Total Asset Value of Company|Company Total Assets ADMA|PTGX (Protagonist Corp) - Aggregate Asset Value|Company Total Assets IMVT (Immunovant, Inc.)|Company Total Assets kiniksa.com KNSA|GRFS - Aggregate Company Assets|Aggregate Asset Value ADPT (Adaptive Biotech)|Celldex (CLDX) - Aggregate Company Assets|Cumulative Company Assets Aurinia Corp|BCRX (BioCryst) - Company Total Assets|Company Total Assets veratx.com|Cumulative Company Assets DNTH (Dianthus Therapeutics, Inc.)|PHVS (Pharvaris NV) - Aggregate Asset Value|Company Total Assets ABCL (abcellera.com)|Company Total Asset Base Tourmaline (TRML)|PGEN - Aggregate Company Assets|pharming.com (PHAR) - Cumulative Company Assets|Nektar Therapeutics Inc. (NKTR) - Aggregate Company Assets|Cumulative Company Assets Upstream Bio, Inc.|Cumulative Company Assets ZBIO|Company Total Assets Immunome Bio|Aggregate Company Assets Gossamer Bio, Inc. (GOSS)|kalvista.com - Total Business Assets|Company Total Assets SEPN (Septerna)|Pieris Pharma (PVLA) - Company Assets|SVRA - Aggregate Company Assets|Aggregate Asset Value RIGL (Rigel Corp)|ANAB: Company Total Assets|astriatx.com (ATXS) - Company Total Assets|Aggregate Company Assets enGene|Aerovate - Total Asset Value of Company|Cumulative Company Assets ACRS (Aclaris)|Aggregate Business Assets KYTX|Tiziana Life Sciences - Cumulative Company Assets|Aggregate Asset Value CABA|VTYX: Cumulative Company Assets|Theratechnologies, Inc. - Aggregate Business Assets|AVTX: Company Total Assets|Eledon Pharmaceuticals, Inc - Aggregate Asset Value|AGEN (Agenus) - Company Total Assets|Company Assets climbbio.com CLYM|Aggregate Company Assets Zura Bio (ZURA)|ATYR (aTyr Pharma Inc) - Aggregate Asset Value|Company Total Assets ADAG (Adagene Inc.)|Company Total Assets ImageneBio IMA|STTK - Aggregate Company Assets|Total Asset Value of Company EQ|CNTB: Company Total Assets|Company Assets Immunic (IMUX)|Cumulative Company Assets ATRA|Company Total Assets InflaRx GmbH|Cumulative Company Assets XFOR (X4 Pharmaceuticals)|Aggregate Business Assets ACET|Company Total Assets CELU (Celularity)|Company Total Asset Base INmune Bio Inc (INMB)|Barinthus Bio - Company Total Assets|Kezar Life Sciences Inc (KZR) - Cumulative Company Assets|SAB Biotherapeutics (SABS) - Aggregate Company Assets|AKTX - Company Total Asset Base|Cumulative Company Assets ENLV|QTTB: Aggregate Asset Value|Company Total Assets GOVX|Company Total Asset Base Edesa Biotech Corp|Aggregate Company Assets iBio, Inc. IBIO|CARM: Total Business Assets|XTL Biopharmaceuticals Ltd. - Company Total Assets|Bolt Biotherapeutics (BOLT) - Cumulative Company Assets|HCWB (hcwbiologics.com) - Cumulative Company Assets|APVO - Company Total Asset Base|Aggregate Company Assets AIM ImmunoTech Inc.|ADTX: Aggregate Asset Value|Company Total Assets GRI|Company Total Assets XORTX Therapeutics Inc (XRTX)|Aggregate Company Assets ReShape Lifesciences HIND|REVB (Revelation Biosciences Corp) - Total Asset Value of Company|INDP: Cumulative Company Assets|scinai.com - Aggregate Business Assets|calcimedica.com (CALI) - Aggregate Company Assets|Total Asset Value of Company AFMD (Affimed N.V.)|ALLK (Allakos Inc) - Company Total Assets|HOOK: Aggregate Asset Value|Company Total Assets IGMS|Company Total Assets iteostherapeutics.com (ITOS)|Aggregate Company Assets Ocean Biomedical OCEA|Aggregate Asset Value TCBP|THRD - Aggregate Company Assets